[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100552521":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":10,"centralContacts":27,"locations":33,"responsibleParty":51,"collaborators":10,"id":53,"slug":10,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":61,"minAge":62,"maxAge":10,"enrollmentInfo":63,"targetDuration":10,"studyType":66,"phases":10,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Centre Hospitalier Régional d'Orléans","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"n°1 (ESKD)",null,"end-stage chronic kidney disease",[13],"Other: 1 blood sample for each participant",{"label":15,"type":10,"description":16,"interventionNames":17},"n°2 (stage 3 CKD)","stage 3 chronic kidney disease",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"n°3 (healthy donors)","healthy donors",[13],[23],{"type":6,"name":24,"description":25,"armGroupLabels":26,"otherNames":10},"1 blood sample for each participant","Blood sample for cohort n°1 and n°2 (collection during a peripheral venous blood sample, part of the standard of care for this disease) :\n\n1 blood sample for each patient 28mL of blood (4 tubes, 7mL per tube)\n\nBlood samples for cohort n°3 (collection during blood donation at Etablissement Français du Sang) :\n\n1 blood sample for each healthy donor 14mL of blood (2 tubes, 7mL per tube)",[9,15,19],[28],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},"Manon DEKEYSER, PhD","CONTACT","+33238229870","manon.dekeyser@chu-orleans.fr",[34],{"facility":35,"status":36,"city":37,"state":10,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Center Hospitalier Universitaire d'Orléans","RECRUITING","Orléans","45067","France","FR",{"type":42,"coordinates":43},"Point",[44,45],1.90407,47.90248,{"lat":45,"lon":44},[48],{"name":29,"role":30,"phone":49,"phoneExt":50,"email":32},"2 38 22 98 29","+33",{"type":52,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100552521",false,"NCT06474169","Assessment of T-cell Response and In-vitro Proof-of-concept of T-cell Engineering in Chronic ESKD Patients.","Assessment of T-cell Response and In-vitro Proof-of-concept of T-cell Engineering in Chronic End-stage Kidney Disease Patients.","LYMPHOVIR-IRCT","Inclusion Criteria:\n\n1. Male or female ≥ 18 years\n2. Informed participants who did not object to participating in the study\n\nExclusion Criteria:\n\n1. Chronic progressive infections\n2. Prior organ transplantation (including bone marrow transplantation)\n3. Previous treatment with immunosuppressive agents (such as Rituximab, Eculizumab, Tacrolimus or Ciclosporin, Cellcept or Imurel) within 2 years prior to inclusion\n4. Participant under guardianship, curatorship or deprived of liberty\n5. Pregnant or breastfeeding women",true,"ALL","18 Years",{"count":64,"type":65},100,"ESTIMATED","OBSERVATIONAL","This is a comparative, prospective, non-interventional study to evaluate immune response in patients with chronic kidney disease. The primary objective is to define immunodeficiency (phenotype and function of T cells) in patients with end-stage kidney disease. The second objective is to provide an in-vitro proof-of-concept of T-cell engineering in the context of end-stage kidney disease.\n\nThe study population was patients with chronic kidney disease.",[69],"Chronic Kidney Diseases",[71,72,73,74],"end-stage kidney disease","T-cells response","Immunodeficiency","Proof of concept of T-cell therapy","2026-06-22",{"date":77,"type":78},"2026-06-25","ACTUAL",{"date":80,"type":78},"2024-11-27",{"date":82,"type":65},"2026-12",{"name":5,"class":6},1]